PEM Imaging With Breast Cancer Specific Tracer (Cu-64-TP3805) Demonstrates 100% Senstivity in Trial Study
Specificity Demonstrated Has Significant Implications for Breast Cancer Management
(firmenpresse) - SAN DIEGO, CA -- (Marketwired) -- 07/24/13 -- Dr. Mathew Thakur, Professor of Radiology and Radiation Oncology at Thomas Jefferson University, having presented on the first "in human" test of cancer specific radiotracer Cu-64-TP3805 at the 2nd World Congress on Ga-68 in February, published early clinical results in the July issue of Journal of Nuclear Medicine. The trial results were also featured at the recent Society of Nuclear Medicine and Molecular Imaging meeting in Vancouver, Canada. TP3805 is a compound, licensed by NuView Life Sciences and named NLS-VPAC1, which binds to the VPAC1 receptors expressed on all breast cancer cells early in malignant transformation. The goal of this compound is to provide "in vivo" imaging for histologic confirmation of malignancy. Whole Body PET-CT and Naviscan's high resolution organ-specific PET scanner, which when applied to breast imaging is called Positron Emission Mammography or PEM, were utilized in this study.
PEM imaging using both Cu-64-TP3805 and F-18-FDG was done in 13 patients. In the entire study, with TP3805, 100 percent of malignant lesions (n=20) inclusive of lymph nodes with metastatic disease were identified using only 4 +/- 10% mCi of Cu-64-TP3805 and imaging 15 minutes post-injection.
Dr. Thakur's research validates the belief that molecular imaging can now be done with low radiation to the patient, fast imaging times and cancer specificity, thereby providing "in vivo" cancer imaging histology, resulting in significant benefits to the patient, eliminating unnecessary invasive procedures such as biopsy, as well as potentially reducing healthcare costs.
"There is a compelling need for a biomolecule that will noninvasively distinguish malignant from benign lesions," states Dr. Thakur. "Cu-64-TP3805 promises to be such an agent and warrants further studies in patients to validate the hypothesis that Cu-64-TP3805 will help reduce the number of unnecessary biopsies."
"Dr. Thakur has made significant strides in proving the feasibility and benefits of a cancer specific tracer," states Paul J. Mirabella, CEO, Naviscan, Inc. "These results show the potential for High Resolution Breast PET imaging to be fast and cancer specific while reducing radiation exposure to the patient. This type of breakthrough has the ability to make a marked change in breast cancer management and moves us into a new era in molecular breast imaging."
If the specificity of 64Cu-TP3805 is validated with future studies, TP3805 imaging with PEM guided biopsy could become the pathway for patient management for abnormalities detected in breast cancer screening.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit .
Joleen Schultz
Naviscan Marketing Communications
Tel: +1.760-271-8150
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.07.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 281272
Anzahl Zeichen: 2911
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Personal Care & Fitness
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PEM Imaging With Breast Cancer Specific Tracer (Cu-64-TP3805) Demonstrates 100% Senstivity in Trial Study"
steht unter der journalistisch-redaktionellen Verantwortung von
Naviscan (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
